Related Experiment Videos
[Diabetes mellitus and atypical antipsychotics]
Eduardo Pondé de Sena1, Aline Santos Sampaio, Lucas de Castro Quarantini
1Departamento de Farmacologia, Universidade Federal da Bahia, Salvador, BA, Brazil. eduponde@ufba.br
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)
|August 26, 2004
Summary
Patients with schizophrenia have an increased risk of hyperglycemia. Atypical antipsychotic drugs may elevate this risk, necessitating careful monitoring and management of glycemic disorders in patients undergoing treatment.
Area of Science:
- Endocrinology and Psychiatry
- Pharmacology
Context:
- Schizophrenic patients exhibit a predisposition to hyperglycemic disorders.
- Antipsychotic medications, particularly atypical agents, are increasingly associated with elevated diabetes mellitus risk.
Purpose:
- To review the relationship between atypical antipsychotic drug use and the incidence of diabetes mellitus.
- To synthesize current evidence on the glycemic risks associated with antipsychotic therapy.
Summary:
- A systematic literature search (1997-2002) using terms like 'Hyperglycemia', 'Diabetes Mellitus', and 'Antipsychotic Agents' identified a significant link.
- Findings indicate a heightened risk of glycemic disturbances in individuals treated with antipsychotic medications.
- The review underscores the importance of considering dietetic interventions and risk factor management during psychiatric treatment.
Impact:
- Highlights the need for proactive metabolic monitoring in patients prescribed antipsychotics.
- Informs clinical practice regarding the potential diabetogenic effects of atypical antipsychotics.
- Emphasizes the critical role of integrated care addressing both mental health and metabolic well-being.